Press Releases

Date Title and Summary Additional Formats
Toggle Summary NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
AMES, Iowa , June 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105 , a Phase 1 study evaluating indoximod in combination with radiation and chemotherapy for the treatment
View HTML
Toggle Summary NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018
AMES, Iowa --(BUSINESS WIRE)--Jun. 4, 2018-- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the  2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting .
View HTML
Toggle Summary NewLink Genetics to Participate in the Jefferies 2018 Global Healthcare Conference
AMES, Iowa , May 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 , at 8:00AM ET .  A live webcast of the presentation will be available on the Company’s
View HTML
Toggle Summary NewLink Genetics Announces Final Results from Phase 2 Studies of Indoximod in Advanced Melanoma and Metastatic Pancreatic Cancer to be Presented at ASCO 2018
AMES, Iowa , May 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that abstracts from two Phase 2 studies of indoximod, used in combination with other agents, are now available on the website of the  2018 American Society of Clinical Oncology ( ASCO ) Annual
View HTML
Toggle Summary NewLink Genetics Reports First Quarter 2018 Financial Results
Management to Host Conference Call Today at 4:30 p.m. ET AMES, Iowa , May 03, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the first quarter 2018 and reviewed recent highlights and upcoming milestones.
View HTML
Toggle Summary NewLink Genetics Appoints Matthew L. Sherman, M.D. to Board of Directors
AMES, Iowa, May 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced the appointment of Matthew L. Sherman, M.D. to the Company's Board of Directors.  In connection with this appointment, the Company's Board will be comprised of eight directors.
View HTML
Toggle Summary NewLink Genetics to Participate in Upcoming Investor Conferences
AMES, Iowa , April 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences: Deutsche Bank 43 rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston   Bank of America Merrill Lynch
View HTML
Toggle Summary NewLink Genetics Announces Presentation of Abstracts at ASCO 2018 Annual Meeting
AMES, Iowa , April 25, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported that two abstracts pertaining to the company's indoximod program will be presented at the American Society of Clinical Oncology ( ASCO ) 2018 Annual Meeting in Chicago.
View HTML
Toggle Summary NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018
AMES, Iowa , April 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its first quarter 2018 financial results on Thursday, May 3 , 2018.  The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.
View HTML
Toggle Summary NewLink Genetics Describes the Differentiated Mechanism of Action of Indoximod in AACR Poster Presentation
AMES, Iowa --(BUSINESS WIRE)--Apr. 17, 2018-- NewLink Genetics Corporation (NASDAQ:NLNK) today presented a poster entitled “Indoximod modulates AhR-driven transcription of genes that control immune function ” in the Immunomodulatory Agents and Interventions session at the American Association for
View HTML